
Breast Cancer
Latest News
Latest Videos

Podcasts
More News


The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.


82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.



Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer



Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.

The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.


Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.





No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.





































































































